Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00510133 · ClinicalTrials.gov registry record · Phase 2

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

A Phase 2 study of Acute Myelogenous Leukemia, sponsored by Asterias Biotherapeutics.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target
6
Study locations

NCT00510133: Completed Phase 2 study of Acute Myelogenous Leukemia, sponsored by Asterias Biotherapeutics.

NCT00510133 is a Phase 2 study of Acute Myelogenous Leukemia that has completed, run by Asterias Biotherapeutics. The registered enrollment target is 21 participants, below the 139-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00510133, a Phase 2 study of Acute Myelogenous Leukemia, has completed, sponsored by Asterias Biotherapeutics.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target
6
Study locations

Study Summary

This is a phase II study to evaluate the safety, feasibility and efficacy of immunotherapy with GRNVAC1 in patients with AML.

Conditions Studied

Acute Myelogenous Leukemia

Interventions

  • BIOLOGICAL GRNVAC1

Study Locations (6)

Georgia

  • Emory University School of Medicine - Atlanta

Illinois

  • Loyola University Medical Center - Maywood

Missouri

  • Washington University School of Medicine, Siteman Cancer Center - St Louis

Nebraska

  • University of Nebraska Medical Center - Omaha

Ohio

  • Ohio State University - Columbus

Texas

  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2007-07
Est. Completion 2014-08
Phase Phase 2
Asterias Biotherapeutics

1 total trials

What the finished NCT00510133 record still lists

NCT00510133 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 139-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which GRNVAC1 is the first listed.

NCT00510133 lists 6 locations in 6 states (Georgia, Illinois, Missouri).

Frequently Asked Questions

What is clinical trial NCT00510133 about?

NCT00510133 is a clinical study titled "A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)". This is a phase II study to evaluate the safety, feasibility and efficacy of immunotherapy with GRNVAC1 in patients with AML.

What is the current status of trial NCT00510133?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-07. Estimated completion is 2014-08.

What conditions does trial NCT00510133 study?

This clinical trial studies the following conditions: Acute Myelogenous Leukemia.

What interventions are being tested in trial NCT00510133?

The interventions under investigation include: GRNVAC1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00510133?

This trial is sponsored by Asterias Biotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00510133 being conducted?

This trial has 6 study locations across Georgia, Illinois, Missouri, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myelogenous Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00510133's enrollment target sits among peer trials

21 38th of 38 higher than 1 of 38 other Acute Myelogenous Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myelogenous Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00510133, the US trial registry maintained by the National Library of Medicine. NCT00510133 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.